This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of trihexyphenidyl
PDMED_TRIHEXYPHENIDYL
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
82 |
4. Check minimum number of events
Min. number of events
3
|
82 |
5. Include endpointsNone |
82 |
6. Filter based on genotype QC (FinnGen only) |
63 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Use of trihexyphenidyl
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 63 | 33 | 30 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | 51.47 | 41.66 | 62.25 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 64
- Matched controls
- 640
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
N04AA01
ATC
trihexyphenidyl; oral
+∞
91.9
64
*
N04AA02
ATC
biperiden; systemic
169.7
38.0
37
5
110
Kela drug reimbursment
Parkinson's disease and comparable movement disrorders
106.5
33.8
35
7
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
64.7
32.6
37
13
N05AA02
ATC
levomepromazine; systemic
49.9
19.6
23
7
G20
ICD-10 Finland
Parkinson disease
49.9
19.6
23
7
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
37.3
19.1
24
10
F20.9
ICD-10 Finland
Schizophrenia, unspecified
61.0
18.7
21
5
Z76.8
ICD-10 Finland
Persons encountering health services in other specified circumstances
28.3
18.4
25
14
N05AF05
ATC
zuclopenthixol; systemic
71.2
18.2
20
*
N05AH03
ATC
olanzapine; systemic
24.7
17.0
24
15
N05AX08
ATC
risperidone; systemic
9.5
15.9
24
38
N05BA01
ATC
diazepam; systemic, rectal
8.4
15.0
26
48
N05BA06
ATC
lorazepam; systemic, sublingual
17.5
14.9
24
21
N05AH02
ATC
clozapine; systemic
+∞
14.1
13
*
N05AH04
ATC
quetiapine; oral
7.2
12.4
24
49
N05AB03
ATC
perphenazine; systemic, rectal
29.8
12.3
16
7
N03AE01
ATC
clonazepam; systemic
17.4
12.1
19
15
F20
ICD-10 Finland
Schizophrenia
145.0
11.9
12
*
N05AF03
ATC
chlorprothixene; systemic
43.9
11.8
14
*
P72
ICPC
Schizophrenia
31.9
10.3
13
5
F20.00
ICD-10 Finland
Paranoid schizophrenia continuous
31.9
10.3
13
5
N04BD01
ATC
selegiline; oral
31.9
10.3
13
5
N05CD07
ATC
temazepam; oral
5.7
9.7
24
61
188
Kela drug reimbursment
Psychosis requiring demanding treatment
+∞
9.6
9
*
29510
ICD-8 Finland
Schizophrenia, Hebephrenic type
+∞
9.6
9
*
N04BB01
ATC
amantadine; oral
58.3
9.0
10
*
N05AX12
ATC
aripiprazole; systemic
32.6
8.8
11
*
F20.0
ICD-10 Finland
Paranoid schizophrenia
103.1
8.6
9
*
F20.1
ICD-10 Finland
Hebephrenic schizophrenia
+∞
8.5
8
*
3320A
ICD-9 Finland
Parkinson's disease, Paralysis agitans
51.5
7.9
9
*
2951C
ICD-9 Finland
Schizophrenic psychoses, Disorganised type[HEBEFREENISTYYPPINEN SKITSOFRENIA,KROONINEN]
+∞
7.4
7
*
A06AD11
ATC
lactulose; oral
4.6
7.4
23
69
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
6.9
7.2
18
34
SPAT1262
SPAT
Handing over of treatment supplies
4.7
7.0
20
56
N04BX02
ATC
entacapone; oral
44.9
6.9
8
*
F20.10
ICD-10 Finland
Raise schizophrenia continuously
77.2
6.6
7
*
ZY000
NOMESCO Finland
Hospital inpatient
77.2
6.6
7
*
G02CB01
ATC
bromocriptine; systemic
30.0
6.4
8
*
ZXE01
NOMESCO Finland
Procedure duration 0 to 9 minutes
30.0
6.4
8
*
U04
ICPC
Incontinence urine
10.2
6.4
12
14
ZXY49
NOMESCO Finland
Other health care provider
+∞
6.3
6
*
AA400
NOMESCO Finland
Electroconvulsive therapy
+∞
6.3
6
*
N06AB04
ATC
citalopram; systemic
4.0
6.3
24
83
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
28
47
9.81
17.82
7.2
3.7
—
—
—
0
0
13
5
31.94
10.28
6.0
1.6
16.32
15.30
%
—
13
5
33
141
3.77
6.40
7.2
2.7
0.00
0.00
estimate
-0.00
21
40
34
150
3.70
6.25
7.7
3.8
0.00
0.00
estimate
-0.00
24
49
10
12
9.63
5.28
6.8
1.1
128.60
122.29
g/l
—
10
7
25
99
3.50
5.28
2.5
2.0
409.38
534.92
pmol/l
1.48
16
89
10
15
7.67
4.67
7.2
2.3
29.43
26.68
mmol/l
—
10
15
10
19
6.02
4.01
1.9
1.4
—
—
—
0
0
11
24
5.31
3.96
7.6
10.6
26.82
25.52
mmol/l
0.30
11
24
35
196
2.73
3.79
7.5
3.8
0.00
0.00
estimate
-0.00
18
46
19
82
2.87
3.31
2.3
2.1
—
—
—
0
0
21
98
2.70
3.15
3.1
1.5
1659.82
1221.70
nmol/l
1.11
11
77
5
6
8.90
2.80
1.4
1.3
—
—
—
0
0
5
10
5.32
2.11
1.4
1.8
—
—
—
0
0
37
258
2.03
2.00
7.9
4.0
0.00
0.00
estimate
-0.00
25
56
5
11
4.83
1.98
2.0
1.3
—
—
—
0
0
8
30
2.90
1.79
1.8
1.7
—
—
—
0
0
20
116
2.05
1.75
2.4
2.2
4.84
2.90
mg/l
0.60
14
101
36
257
1.92
1.74
8.1
3.9
0.00
0.00
estimate
-0.00
21
55
5
14
3.78
1.64
1.4
2.2
—
—
—
0
0
36
262
1.85
1.59
7.6
4.0
0.00
0.00
estimate
-0.00
25
49
22
143
1.82
1.35
1.5
1.7
16.55
20.42
nmol/l
0.40
17
117
12
63
2.11
1.33
1.7
2.0
—
—
—
0
0
5
111
0.40
1.28
2.0
2.6
—
—
—
0
0
25
172
1.74
1.27
2.8
2.9
57.63
55.42
u/l
0.14
19
157
35
265
1.71
1.26
17.6
11.6
4.36
3.96
e9/l
0.52
30
225
32
237
1.70
1.24
6.9
7.4
1.22
1.21
mmol/l
0.30
18
212
12
66
2.01
1.18
1.7
1.9
—
—
—
0
0
23
175
1.49
0.72
2.0
3.6
2.37
2.35
mmol/l
0.27
17
156
39
444
0.69
0.67
5.0
5.6
3.90
4.56
mmol/l
3.64
27
412
37
425
0.69
0.67
3.8
4.6
1.12
1.30
mmol/l
1.25
24
394
12
170
0.64
0.65
4.8
5.7
1.43
2.05
ug/l
—
7
141
0
19
0.00
0.61
0.0
1.8
—
3.69
—
0
14
0
22
0.00
0.60
0.0
1.0
—
—
—
0
0
0
23
0.00
0.59
0.0
1.4
—
—
—
0
0
27
227
1.33
0.45
3.0
2.9
—
—
—
0
0
41
450
0.75
0.43
5.0
6.3
2.08
2.62
mmol/l
2.90
29
419
40
440
0.76
0.42
4.8
5.4
1.46
1.48
mmol/l
0.17
28
407
0
15
0.00
0.42
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.7
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.2
—
—
—
0
0
18
219
0.75
0.40
3.1
3.0
—
—
estimate
—
0
0
5
76
0.63
0.38
11.4
7.1
100.00
104.07
mmol/l
—
5
76
21
174
1.31
0.38
3.1
3.7
1567.00
1376.82
ng/l
0.12
15
152
41
443
0.79
0.32
6.0
5.6
6.36
6.00
mmol/l
0.73
32
412
38
347
1.23
0.29
4.4
4.8
10.75
11.86
mm/h
0.21
32
309
0
11
0.00
0.21
0.0
1.4
—
159.44
—
0
5
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
5
66
0.74
0.18
2.6
1.3
—
—
—
0
0
41
432
0.86
0.17
7.8
6.6
41.84
39.71
mmol/mol
0.57
32
408
40
379
1.15
0.15
6.3
9.1
99.47
81.99
u/l
0.32
34
352
5
44
1.15
0.10
1.2
2.0
1.66
1.56
%
—
5
37
14
152
0.90
0.07
1.9
4.0
21.43
28.49
u/l
4.10
14
142
43
441
0.92
0.05
26.9
16.5
81.95
76.26
ml/min/173m2
1.03
43
413
20
209
0.94
0.03
2.1
2.4
69.86
76.87
nmol/l
0.44
14
183
20
206
0.96
0.00
1.6
2.1
93.81
92.72
pmol/l
0.04
13
99
18
181
0.99
0.00
2.6
2.0
1.33
1.43
mmol/l
0.22
12
144
5
54
0.92
0.00
4.4
3.6
6.88
5.72
kpa
—
5
54
0
5
0.00
-0.00
0.0
1.0
—
2.35
—
0
5
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
7.7
—
179.78
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
43.62
—
0
6
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
845.60
—
0
5
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
277.71
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
9.33
—
0
6
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
18.40
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
192.67
—
0
9
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: PDMED_TRIHEXYPHENIDYL – Use of trihexyphenidyl
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).